Ception Therapeutics was acquired by Cephalon Inc. in March 2010 in a deal worth $350 million plus significant future millstones. Cephalon Inc. was subsequently acquired by Teva in 2011.
Trending at Lumira Ventures
Corus Pharmaceuticals, developer of Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependent asthma, was acquired by Gilead in August 2006 for $365 million.
Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005.
Guava Technologies was acquired by Millipore Inc. in February 2009.
From the time we invested in 2002 to our exit in 2006, ISTA Pharmaceuticals launched 3 products in the United States to treat diseases of the eye.
KAI Pharmaceuticals Inc., developer of novel therapeutics for kidney disease, was acquired by Amgen in 2012 for US$315 million.
Morphotek was acquired by Eisai Inc. in April 2007 for $325 million.
Resonant Medical, developer of 3D ultrasound image-guided radiotherapy products, was acquired by Elekta in May of 2010.
Spinal Kinetics, developer of artificial discs for degenerative diseases of the spine, was acquired by Orthofix in March 2018.
Think Research develops knowledge-based and leading clinical content tools that empower clinicians to deliver the best evidence-based care to patients and drive better patient outcomes.
Automated Breast Ultrasound company, U-Systems, was acquired by GE Healthcare Limited in November 2012.